Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 11, 2026

Aduro Clean Technologies gibt Ausgabepreis für ein garantiertes öffentliches Emissionsangebot in Höhe von 15,64 Millionen US-Dollar sowie eine gleichzeitige Privatplatzierung von bis zu 7,17 Millionen US-Dollar bekannt

View original at globenewswire.com
Aduro Clean Technologies gibt Ausgabepreis für ein garantiertes öffentliches Emissionsangebot in Höhe von 15,64 Millionen US-Dollar sowie eine gleichzeitige Privatplatzierung von bis zu 7,17 Millionen US-Dollar bekannt LONDON, Ontario, June 11, 2026 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The company intends to rely on the exemption under Section 602.1 of the TSX Company Manual, which provides that the TSX does not apply its standards to certain transactions involving eligible issuers listed on a recognized exchange.

    60% confidence
  • Aduro's Hydrochemolytic™ technology uses water as the primary active ingredient in a chemical platform that operates at relatively low temperatures and costs.

    60% confidence
  • Aduro intends to use net proceeds from the offering for planning, development, and construction of the world's first industrial-scale FOAK demonstration facility, ongoing R&D expenses, and remaining amounts for general corporate purposes and working capital.

    60% confidence
  • The company anticipates that certain insiders may participate in the LIFE offering, constituting a 'related party transaction' under MI 61-101, but expects to rely on exemptions from formal valuation and minority shareholder approval requirements as insider participation is not expected to exceed 25% of the company's market capitalization.

    60% confidence
  • The public offering is expected to close on or about June 11, 2026, subject to satisfaction of customary closing conditions, including listing of offered shares on the TSX and Nasdaq and receipt of all required TSX and Nasdaq approvals.

    60% confidence
  • The LIFE offering is expected to close on or about the closing date or another date determined by the company, but no later than 45 days after the date of this press release. The LIFE offering may close in one or more tranches.

    60% confidence
  • The public offering is not conditional on completion of the LIFE offering, and the LIFE offering is not conditional on completion of the public offering.

    60% confidence

Data points we hold from this source

Aduro Clean Technologies Inc. · gross proceeds life offering7169810 USD
Aduro Clean Technologies Inc. · gross proceeds public offering15635404 USD
Aduro Clean Technologies Inc. · shares offered public1028645 shares
Aduro Clean Technologies Inc. · shares offered life private placement471698 shares
Aduro Clean Technologies Inc. · offer price usd15.20 USD_per_share
Aduro Clean Technologies Inc. · offer price cad21.20 CAD_per_share
Aduro Clean Technologies Inc. · gross proceeds total combined22805214 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Aduro Clean Technologies gibt Ausgabepreis für ein garantiertes öffentliches Emissionsangebot in Höhe von 15,64 Millionen US-Dollar sowie eine gleichzeitige Privatplatzierung von bis zu 7,17 Millionen US-Dollar bekannt — Source | Via News | Finance Via News